Company Filing History:
24 out of 3,693 
3 out of 1,942 
Years Active: 1998-2021
Title: Innovations in Cancer Therapy: The Contributions of Stephen B Baylin
Introduction: Stephen B Baylin, based in Baltimore, MD, is a prominent figure in the field of cancer research and epigenetics. With an impressive portfolio of 24 patents, he has made significant contributions to the development of innovative therapies for cancer treatment. His work focuses on combining epigenetic modulation with immune modulation to improve patient outcomes.
Latest Patents: Baylin's latest inventions include groundbreaking methods for cancer therapy. One notable patent details a cancer therapy that utilizes a combination of epigenetic and immune-modulating agents. This approach has shown remarkable potential in treating non-small cell lung cancer (NSCLC) by enhancing the efficacy of treatments with agents such as anti-PD-1 and anti-PD-L1 antibodies when paired with the epigenetic modulating agent 5-deoxyazacytidine. Another significant patent involves predicting patient responses to epigenetic drug therapy through a unique signature known as the AZA Immune gene set or AIM. This innovation distinguishes between patients with low and high immune signatures, guiding tailored treatments that optimize the effectiveness of both epigenetic drugs and subsequent immunotherapy.
Career Highlights: Throughout his career, Baylin has been affiliated with The Johns Hopkins University School of Medicine and The Johns Hopkins University, where he has conducted extensive research in the field of epigenetics. His dedication to advancing cancer therapies has positioned him as a leading inventor in this domain, and his patents reflect his commitment to improving treatment strategies for cancer patients.
Collaborations: Baylin has collaborated with notable colleagues, including James Gordon Herman and Michele Makos Wales. These partnerships have fostered a collaborative research environment that encourages innovation and the cross-pollination of ideas, ultimately benefiting the field of cancer therapy.
Conclusion: Stephen B Baylin's contributions to the field of cancer research through his patents highlight his innovative approach to treatment. By integrating epigenetic and immune modulation, his work has the potential to change the landscape of cancer therapies, offering new hope to patients facing challenging diagnoses. His ongoing research and development signify the importance of collaboration and innovation in the relentless fight against cancer.